Find Neurology Drugs in Phase I/II Clinical Development

Lead Product(s): Ravulizumab

Therapeutic Area: Neurology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 14, 2020

Details:

A 50-week global study to enroll approximately 350 patients across broad ALS population.

Lead Product(s): AXO-Lenti-PD

Therapeutic Area: Neurology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

AXO-Lenti-PD was observed to be well-tolerated with no serious adverse events attributable to the gene therapy.

Lead Product(s): AstroRx

Therapeutic Area: Neurology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 02, 2020

Details:

A statistically significant decline in disease progression was observed during the first 3- 4 months post-treatment period, indicating a clinical benefit of the AstroRx® cell product.